No Detail Found!

A Literature Review of the Janus Kinase Inhibitors Used in the Treatment of Auto-Immune Dermatological Conditions

Author(s)
Mohammed Al Abadie North Cumbria integrated care NHS Foundation Trust, Clinical Director & Consultant Dermatologist, UK
Zinah Sharara National Health Service (NHS), Community Dermatology Clinics (Health Harmonie), United Kingdom UK
Patrick A Ball School of Pharmacy, University of Wolverhampton, United Kingdom
Hana Morrissey School of Pharmacy, University of Wolverhampton, United Kingdom
Abstract
The signal transducer and activator of transcription (STAT) families and Janus kinase group (JAK) are important intracellular signalling components that affect more than 50 cytokines and growth elements. JAK inhibitors target distinct receptor-associated kinases, inhibiting the activation of inflammatory signals. With the expanding body of evidence supporting the use of targeted medicines, numerous JAK inhibitors, both topical and systemic, have been tested in the treatment of atopic dermatitis, with varying mechanisms of action, effectiveness, and safety. The efficacy and safety of JAK inhibitors used to treat inflammatory and atopic skin diseases are examined in this review study. Their application in the mentioned fields has been characterized by some excellent clinical responses, but wide variability in responses and some serious and even life-threatening side effects. While JAK inhibitors are now beneficial to many patients, further study is needed to better understand this complicated mechanism to improve treatment outcomes and minimize side effects.
Publication Details
Page(s) 37-42
Published Journal: Archives of Pharmacy Practice, Volume: 13, Issue: 2, Year: 2022

Request the full text from PASTIC

Keywords
Atopic dermatitis, Janus kinase, JAK inhibitors, Topical applications, Inflammatory signals
0

Citations

0

Downloads

51

Views